Psychotrauma Prevention Algorithm : Randomized, Controlled Pilot Study (A2P)

A randomized pilot study which proposes to patients having suffered a traumatic event to have either only the standard care or the standard care associated with adaptated psychotrauma watch and prevention system.

Study Overview

Status

Not yet recruiting

Study Type

Interventional

Enrollment (Estimated)

40

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Person who the vital prognosis has or could have been committed or having felt a threat to his physical and/or psychological integrity
  • After a potentially traumatic event dating from a minimum of 72 hours to a maximum of 1 week
  • for which the CUMP or the psychotrauma regulation platform has been requested
  • having lived or being a direct witness of the event
  • knowing how to read and write
  • affiliate or beneficiary of a social security scheme
  • having signed a consent

Non-inclusion Criteria:

  • guardianship or curatorship
  • unable to receive phone calls
  • unable to go to a place for consultation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Prevention algorithm
Patient will have the current support for psychotrauma and psychotrauma prevention algorithm.
a health watch adapted to stress and dissociative symptoms
Active Comparator: Current support for psychotrauma
Patient will have the current support for psychotrauma.
Standard care for post traumatic stress disorder

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
study acceptability rate
Time Frame: 6 months after inclusion

Number of included patient divided by number of patients to whom the study was offered.

Study acceptability rate of 50% is expected.

6 months after inclusion

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Adherence of patient to the watch
Time Frame: 1 month after inclusion
Number of patient contacted by phone having completed the scales divided by number of patient contacted.
1 month after inclusion
Adherence of patient to the health watch
Time Frame: 3 months after inclusion
Number of patient contacted by phone having completed the scales divided by number of patient contacted
3 months after inclusion
Patient satisfaction (quantitatif)
Time Frame: 3 months after inclusion
A questionnaire will be completed by the patient
3 months after inclusion
Patient satisfaction (qualitatif)
Time Frame: 3 months after inclusion
semi-structured interview carried-out in 3 patients volunteers (45 minutes)
3 months after inclusion
Strong points of the health watch
Time Frame: 3 months after inclusion
semi-structured interview carried-out in volunteer caregivers (doctor, nurse, psychologist)
3 months after inclusion
Evolution of the patient journey in experimental arm
Time Frame: 3 months after inclusion
number an percentage of patient who have changed watch
3 months after inclusion
Occurrence of post-traumatic stress disorder
Time Frame: 3 months after inclusion
Evaluation by Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5). Score between 0 and 80. Score < 38 : no post-traumatic stress disorder Score = or > 38 : post-traumatic stress disorder
3 months after inclusion
Complications associated with post-traumatic stress disorder
Time Frame: at inclusion
assessed by C-SSRS (Columbia-Suicide Severity Rating Scale). Assessment of suicide risk in patient. No score for this scale.
at inclusion
Complications associated with post-traumatic stress disorder
Time Frame: 3 months after inclusion
assessed by C-SSRS (Columbia-Suicide Severity Rating Scale). Assessment of suicide risk in patient. No score for this scale.
3 months after inclusion
Complications associated with post-traumatic stress disorder
Time Frame: 3 months after inclusion

assessed by the Hospital Anxiety and Depression Scale (HADS). 1 subscore for anxiety scale (HADS-A) between 0 and 21

1 subscore for depression scale (HADS-D) between 0 and 21 Overall score between 0 and 42 HADS-A + HADS-D scores). Score < or = 7 : no symptom Score = or > 8 : symptom the higher the score, the more severe the symptoms

3 months after inclusion
Complications associated with post-traumatic stress disorder
Time Frame: 3 months after inclusion

assessed by WHO Quality of life - Bref (WHOQOL Bref). This scale assessed 4 domains : physical health, mental health, social relations and the environment.

Overall Score is between 26 and 130. the higher the score, the better the quality of life

3 months after inclusion

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

June 1, 2026

Primary Completion (Estimated)

November 1, 2026

Study Completion (Estimated)

November 1, 2026

Study Registration Dates

First Submitted

April 2, 2024

First Submitted That Met QC Criteria

April 11, 2024

First Posted (Actual)

April 15, 2024

Study Record Updates

Last Update Posted (Actual)

March 19, 2026

Last Update Submitted That Met QC Criteria

March 17, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Psychological Trauma

Clinical Trials on prevention algorithm

Subscribe